

Acknowledgements

DIAMOND PARTNER



ASSOCIATE PARTNER



EXECUTIVE PARTNER



SUPPORTER PARTNER



CONTRIBUTOR PARTNER



EDUCATIONAL GRANTS

Supported by a grant from Pfizer, Inc.

Acknowledgements

ABBOTT

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

AMARIN

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin's lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.

<https://amarincorp.com/>

AMERICAN REGENT

American Regent, Inc. (ARI), a Daiichi-Sankyo Group Company, is a pharmaceutical company focused on sterile injectable products in human and animal health. Our diverse portfolio in human health includes our intravenous iron franchise and a portfolio with branded and generic products. For ARI's iron franchise, our Injectafer life cycle management program is focused on the treatment of iron deficiency anemia in adult and pediatric populations and the treatment of patients in heart failure with iron deficiency.

www.americanregent.com

AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

APPLIED THERAPEUTICS

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company's lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM in September 2019. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial in June 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.

<https://www.appliedtherapeutics.com/>

ASTRAZENECA

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide. www.astrazeneca.com

www.abbott.com

BOEHRINGER INGELHEIM

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found in our annual report: <http://annualreport.boehringer-ingelheim.com>.

www.boehringer-ingelheim.com

BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

www.bms.com

BOSTON SCIENTIFIC

ABoston Scientific is a leading innovator of medical solutions improving health of patients around the world. Our products and technologies are used to diagnose or treat wide ranges of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. We continue to innovate in these areas and extend our innovations into new geographies and high-growth markets.

www.bostonscientific.com

CERENO SCIENTIFIC

Cereno Scientific is developing a pipeline of cardiovascular therapeutics that work through the exciting new field of epigenetic modulation. Cereno's lead program, CS1, is a dual-action anti-thrombotic in Phase 2 development for the prevention of deep vein thrombosis and stroke prevention in atrial fibrillation (SPAF). Cereno is also exploring epigenetic modulation for several orphan disease indications related to lung fibrosis, thrombosis, inflammation and pulmonary hypertension. Cereno is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions.

More information is available at www.cerenoscientific.com

CVRx

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota. The company has developed the second-generation BAROSTIM NEO, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States. The company's BAROSTIM NEO LEGACY™ holds Humanitarian Device Exemption (HDE) approval from FDA, deeming it safe for use in hypertensive patients who were responders to the first-generation BAROSTIM THERAPY with Rheos Carotid Sinus Lead System.

www.cvr.com

CYTOKINETICS

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility, including omecamtiv mecarbil, our Phase 3 drug candidate for people living with heart failure being developed in collaboration with Amgen; reldesemtiv, our Phase 2 drug candidate for people living with SMA and ALS being developed in collaboration with Astellas; CK-274, a novel cardiac myosin inhibitor for which an IND was recently filed; and CK-601, a next-generation FSTA recently advanced into IND-enabling studies. Our muscle biology drug discovery and development platform has great potential for many other diseases and medical conditions characterized by muscle weakness, fatigue, or diminished muscle function.

www.cytokinetics.com

CYTOSORBENTS

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care company specializing in blood purification in critical care and cardiac surgery patients. CytoSorbents had trailing 12-month product sales of \$34.5M, up 51% from a year ago, and was named to the Deloitte Fast 500 for the 4th year in a row as one of top 500 fastest growing companies across all industries in North America. The Company's flagship product, CytoSorb®, is approved in the European Union with distribution in 66 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. CytoSorb® is also being used in cardiac surgery to remove inflammatory mediators, and recently completed a label expansion for the removal of antithrombotic agents such as ticagrelor and rivaroxaban, to reduce the risk of post-operative complications. CytoSorb® has been used safely in more than 110,000 human treatments to date. CytoSorbents' blood purification technologies are based on advanced, bio-compatible, highly porous polymer beads that can actively remove toxic substances from blood by pore capture and surface adsorption. Each polymer bead, approximately the size of a grain of salt, contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies from blood.

www.cytosorbents.com

DAIICHI SANKYO

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

www.daiichisankyo.com

EDWARDS LIFESCIENCES

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its life saving innovations, which are sold in approximately 100 countries. Many of the company's products are considered industry «gold standards» and over 95 percent of its sales are from products in leading market positions. Edwards has extensive manufacturing operations in North America, Europe, Singapore and the Caribbean.

www.edwards.com

ELI LILLY AND COMPANY

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and <http://newsroom.lilly.com/social-channels>. P-LLY

GEORGE CLINICAL

George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 300 people managing 38 locations throughout the USA, Asia-Pacific and Europe, George Clinical provides comprehensive clinical trial services in the cardiometabolic space to biopharmaceutical and medical device customers, for all trial phases.

<https://www.georgeclinical.com>

JANSSEN

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at [www.twitter.com/JanssenGlobal](https://twitter.com/JanssenGlobal).

www.janssen.com

KBP BIOSCIENCES

KBP Biosciences is a global, clinical stage biopharmaceutical company focused on the development of an innovative pipeline of new chemical entities with known mechanisms of action targeting underserved patient populations in organ protection and infectious diseases. KBP utilizes an integrated discovery and development platform that enables the Company to efficiently bring new therapies from bench to patients around the world.

www.kbpbiosciences.com

LIVANOVA

LivaNova is a market-leading medical technology company with cardiovascular and neuromodulation businesses and approximately 4,000 employees in more than 100 countries. We have been pioneers in neuromodulation, providing VNS (Vagus Nerve Stimulation) Therapy® Systems for drug-resistant epilepsy and treatment-resistant depression, and are currently evaluating the ability of VNS to deliver Autonomic Regulation Therapy for heart failure. Other solutions using neurostimulation include the engagement of tongue muscles via the hypoglossal nerve with an implantable device for the treatment of obstructive sleep apnea (OSA). We also offer the only truly sutureless aortic valve replacement, and are recognized as the world's #1 company for cardiac and cardiopulmonary bypass and support products.

www.livanova.com

MICROPORT

MicroPort® created drug-eluting stents that are available in 36 countries around the world and is imagining how they would impact the lives of people through technology. Their belief was that these medical technologies must be accessible to everyone. Relentless innovation has inspired promising product development and initiated strategic investments in emerging scientific platforms. Today, we see a promising path forward, one that addresses the most challenging healthcare issues, while allowing us to explore the ways to accelerate and broaden access to medical technology innovation.

www.microport.com

MEDTRONIC

Medtronic is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries.

www.medtronic.com

NOVO NORDISK

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in 165 countries.

www.novonordisk.com

NOVARTIS

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

www.novartis.com

OLINK

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics provides outstanding products and services for targeted human protein biomarker discovery. We help scientists get answers quickly and confidently through robust, multiplex biomarker analysis. Olink immunoassay panels enable rapid, high-throughput analysis, with exceptional data quality and minimal sample consumption. Using just 1 µl of sample, 92 biomarkers are assayed simultaneously, with up to 96 samples run per panel. Our Proximity Extension Assay (PEA) technology enables this high level of multiplexing, as this dual recognition, DNA-coupled method provides exceptional readout specificity. Disease area or biological process-focused panels have both validated and exploratory biomarkers, and our rigorous assay validation data is freely available. Choosing either ready-to-use kits or our Analysis Service, customers get high quality data and rapid high-throughput analysis that makes the most effective use of their precious samples.

www.olink.com

PFIZER

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

www.pfizer.com

RELYPSA

Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the development and commercialization of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. Relypsa is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions that are often overlooked and undertreated.

More information is available at www.relypsa.com.

ROCHE

A global leader in healthcare with combined strengths in diagnostics and pharmaceuticals, Roche is focused on doing now what patients need next. As the world's largest provider of NT-proBNP and Troponin T cardiac biomarker testing, Roche solutions play a critical role in helping to diagnose heart failure and acute coronary syndrome. Roche's portfolio includes the first, and only, FDA-cleared high sensitivity troponin T assay in the US market today.

We also lead the way in developing truly differentiated healthcare solutions that are focused on increasing medical value and testing efficiency. Our research tools, tests, and customized treatments enable personalized healthcare solutions, tailored to the needs of unique groups of patients.

www.roche-diagnostics.us

TERUMO

Terumo Corporation was founded in 1921 by several scientists and doctors, including Dr. Shibasaburo Kitasato, to produce clinical thermometers in Japan. We contribute to society by providing valued products and services in the healthcare market and by responding to the needs of patients and healthcare professionals.

www.terumo.com

VIFOR PHARMA GROUP

The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. The Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange.

www.viforpharma.com